Janssen Research & Development has submitted an FDA new drug application for the approval of an investigational HIV drug combination. The treatment consists of Prezista, a protease inhibitor that prevents viral replication, and cobicistat, a drug that slows the process of eliminating vital protease inhibitors from the body, this article says.

Related Summaries